Cargando…

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors, also called gliflozins or flozins, are a class of drugs that have been increasingly used in the management of type 2 diabetes mellitus (T2DM) due to their glucose-lowering, cardiovascular (CV), and renal positive effects. However, recent studies su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koutentakis, Michail, Kuciński, Jakub, Świeczkowski, Damian, Surma, Stanisław, Filipiak, Krzysztof J., Gąsecka, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672595/ https://www.ncbi.nlm.nih.gov/pubmed/37998523 http://dx.doi.org/10.3390/jcdd10110465

Ejemplares similares

The Effect of a Vegan Diet on the Cardiovascular System
por: Koutentakis, Michail, et al.
Publicado: (2023)

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
por: Kochanowska, Anna, et al.
Publicado: (2023)

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023)

Is colchicine the holy grail for treating inflammation and reducing cardiovascular risk?
por: Filipiak, Krzysztof J., et al.
Publicado: (2021)

Inflammation and autoimmunity in atherosclerosis
por: Surma, Stanislaw, et al.
Publicado: (2022)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

Ranolazine - could an antianginal drug be used in stroke prevention?
por: Surma, Stanisław, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

The Role of the Gut Microbiota on the Beneficial Effects of Ketogenic Diets
por: Attaye, Ilias, et al.
Publicado: (2021)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

Heart Failure—Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10
por: Filipiak, Krzysztof J., et al.
Publicado: (2022)

Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
por: Gawlik, Michał, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature
por: Mistry, Serena, et al.
Publicado: (2020)

Colchicine — From rheumatology to the new kid on the block: Coronary syndromes and COVID-19
por: Surma, Stanisław, et al.
Publicado: (2023)

Coffee and cardiac arrhythmias: Up-date review of the literature and clinical studies
por: Surma, Stanisław, et al.
Publicado: (2023)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question
por: Sobierajski, Tomasz, et al.
Publicado: (2022)

A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed
por: Steinmetz-Wood, Samantha, et al.
Publicado: (2020)

Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
por: Lymperopoulos, Anastasios, et al.
Publicado: (2021)

Assessment of the Effect of A-PRF Application during the Surgical Extraction of Third Molars on Healing and the Concentration of C-Reactive Protein
por: Nowak, Jacek M., et al.
Publicado: (2021)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?
por: Rogula, Sylwester P., et al.
Publicado: (2020)

Harmful and Beneficial Role of ROS
por: Di Meo, Sergio, et al.
Publicado: (2016)

Elderly Obesity: Is It Harmful or Beneficial?
por: Kim, Tae Nyun
Publicado: (2018)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Beneficial effects of SGLT2 inhibitor on metabolic inflexibility and visceral fat amount in animal model of obese type 2 diabetes
por: Hara, Kento, et al.
Publicado: (2022)

Periodontitis, Blood Pressure, and the Risk and Control of Arterial Hypertension: Epidemiological, Clinical, and Pathophysiological Aspects—Review of the Literature and Clinical Trials
por: Surma, Stanisław, et al.
Publicado: (2021)

Beneficial Effects of Ketogenic Diet on Phosphofructokinase Deficiency (Glycogen Storage Disease Type VII)
por: Similä, Minna E., et al.
Publicado: (2020)

Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases
por: Kovács, Zsolt, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021)

Harmful and Beneficial Role of ROS 2017
por: Di Meo, Sergio, et al.
Publicado: (2018)

Harmful and Beneficial Role of ROS 2020
por: Di Meo, Sergio, et al.
Publicado: (2022)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Ketogenic Diet and Epilepsy
por: Ułamek-Kozioł, Marzena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_618nqi0goof923pue5smc9qim1